China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with fellow domestic firm Xiling Lab for the commercialization of its generic version of the breast cancer treatment eribulin, originally marketed as Halaven by Eisai. The agreement grants Xiling commercial and supply rights in 36 countries, including Brazil, Argentina, Singapore, Thailand, Egypt, South Africa, India, and Saudi Arabia.
BrightGene Bio-Medical Technology Co., Ltd. was the first company to secure approval for a generic version of eribulin in China in February 2023. This treatment is indicated for patients with locally advanced or metastatic breast cancer who have undergone at least two prior chemotherapy regimens, as well as those with unresectable or metastatic liposarcoma who have received anthracycline-based therapies.- Flcube.com
